CorePharm succeeds in avoiding Astellas’ patent by salt modification
While a series of domestic companies’ challenges to substance patents all went in vein after implementation of the Patent Linkage System on March 2015, a ruling was made in favor of a Korean challenger at the defensive confirmation trial for the scope of the substance patent of a urinary incontin...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
